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Cisplatin-based chemotherapy has been the established tool for
palliative treatment of advanced non-small cell lung cancer
(NSCLC) patients. A retrospective analysis of trials conducted by
the Southwest Oncology Group (Albein et al, 1991) and a meta-
analysis showed that cisplatin-based chemotherapy significantly
improved survival as compared with the best supportive care
(NSCLC Collaborative Group, 1995). However, cisplatin is asso-
ciated with side-effects that, in some cases, are not easily managed
and that probably negatively affect patients’ quality of life. This
fact is particularly important, because chemotherapy cannot cure
advanced NSCLC and its major objective is palliation
(Ruckdeshel et al, 1998).
In the last few years, new active drugs have been introduced
into the treatment of NSCLC, i.e. vinorelbine, gemcitabine, pacli-
taxel, docetaxel and irinotecan. Such new drugs are being
combined, mostly empirically, in an attempt to identify active,
low-toxic, non-cisplatin-containing regimens. Among the possible
combinations, gemcitabine plus vinorelbine (Gem Vin) is particu-
larly promising due to the low toxicity of both drugs and to their
efficacy as single agents in randomized clinical trials (Depierre et
al, 1994; LeChevalier et al, 1994; Manegold et al, 1997; Perng et
al, 1997; Sandler et al, 1998; ELVIS Group, 1999).
The aim of the present study was to evaluate toxicity and
activity of the Gem Vin combination at four planned dose-levels in
order to select the optimal combination to be compared with
cisplatin-based chemotherapy in a subsequent randomized trial.
PATIENTS AND METHODS
Eligibility criteria
Patients with good performance status (Eastern Cooperative
Oncology Group (ECOG) ≤ 2), below 70 years-of-age, with stage
IV or IIIb (with pleural effusion or metastatic supraclavicular
lymph nodes) NSCLC were eligible. The diagnosis of NSCLC had
to be cytologically or histologically confirmed. Exclusion criteria
were the presence of brain metastaes, previous chemotherapy, a
history of another cancer (excluding non-melanomatous skin
cancer and in situ cervical cancer), reduced bone marrow or renal
or hepatic function, and refusal of informed consent. The protocol
was approved by the ethics committees of the participating institu-
tions. Patients without measurable disease could be entered in the
feasibility part of the study (see below), while they were not
eligible for the phase II evaluation.
Treatment
Gemcitabine and vinorelbine were both given intravenously on
days 1 and 8 of a 21-day cycle. Dose-levels were as follows:
gemcitabine 1000 mg m–2 + vinorelbine 25 mg m–2 (level I), gemc-
itabine 1200 mg m–2 + vinorelbine 25 mg m–2 (level II), gemc-
itabine 1000 mg m–2 + vinorelbine 30 mg m–2 (level III) and
gemcitabine 1200 mg m–2 + vinorelbine 30 mg m–2 (level IV). At
an dose-level, treatment was administered for a maximum of six
cycles. Treatment was interrupted earlier if progression of the
disease was observed. At days 1 and 8, the minimum requirements
for chemotherapy were a neutrophil count of 1.5 × 109 l–1 or more,
a platelet count of 100 × 109 L–1 or more, a haemoglobin level of
8.0 g dL–1 or more, and no sign of organ toxicity (excluding
alopecia). If one or more requirements were absent at day 1,
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tigators were free to choose the treatment strategy. Chemotherapy
was omitted on day 8 if the required haematological parameters
were not met. Toxicity and the patient’s refusal also resulted in
discontinuation of treatment. Antiemetic treatment was provided
with standard-dose 5-HT3 antagonists given before chemotherapy
administration. Palliative radiotherapy could be delivered, if
needed; however, the protocol suggested that contemporaneous
chemotherapy and radiotherapy be avoided because of the risk of
cumulative toxicity. No second-line treatment was planned by
protocol. No prophylactic use of haemotopoietic colony-stimu-
lating factors was planned.
Staging and follow-up procedures
Before entering the study, all patients underwent a clinical exami-
nation that included a PA and lateral chest radiographs, computed
tomography of the thorax and abdomen, and a bone scintigram for
assessment of disease extension. Before each cycle, patients
underwent a clinical examination and a routine biochemistry eval-
uation that included AST, ALT, bilirubin, alkaline phosphatase,
LDH, creatinine, BUN, glucose, uric acid, electrolytes, urine
examination and complete blood count. At baseline and after the
third and sixth cycles an ECG was performed. Restaging was
planned at the end of the third and sixth cycles.
Toxicity and response evaluation
World Health Organization (WHO) criteria (Miller et al, 1981) were
used to categorize toxicity, and the worst degree of toxicity experi-
enced throughout the treatment was computed for each patient.
Response was evaluated at the end of the third and sixth cycles of
treatment by repeating staging procedures. The best response was
recorded for each patient. For clinically evident or suspected progres-
sion of the disease, response evaluation was anticipated. Complete
response was defined as the disappearance of all known sites of
disease. Partial response was defined as decrease of 50% or more in
the sum of products of the largest perpendicular diameters of measur-
able lesions, with no appearance of new lesions and no progression
of any lesion. Stable disease was defined as a decrease of less than
50% or an increase of less than 25% in the sum of products of the
largest perpendicular diameters of measurable lesions with no
appearance of any new lesion. Progressive disease was defined as a
25% or more increase in the size of one or more measurable lesions,
or the appearance of a new lesion. Confirmation of a response after 1
month was not performed. The objective response rate was defined
as the proportion of complete and partial responses.
Quality of life assessment
The European Organization for Research and Treatment of Cancer
(EORTC) core questionnaire (QLQ-C30) and lung-cancer-specific
module (QLQ-LC13) were used for quality of life (QoL) evalua-
tion. A baseline assessment was planned in the phase II study
before each cycle of chemotherapy. The EORTC QLQ-C30 ques-
tionnaire consists of multi-item functioning scales and both multi-
and single-item scales for the evaluation of general cancer-related
symptoms (Aaronson et al, 1993). The EORTC QLQ-LC13
module consists of single items that evaluate specific symptoms of
lung cancer (Bergman et al, 1994). Due to the non-formally
comparative study design, QoL analysis was only descriptive. The
data reported in this paper are only related to the global health
status score (items 29 and 30) and are focused on the description of
the relationship between mean scores and the overall number of
questionnaires completed. A higher value score reflects a better
level of quality of life.
Study design
Because a formal phase I study of the combination was not yet
published at the time of protocol writing, a feasibility phase was
planned at each of the four dose-levels. Feasibility was performed
by one centre (NCI, Naples, Italy) while the phase II multicenter
recruitment sequentially started at each dose level immediately
after feasibility of that level had been assessed. It was planned that
after completion of feasibility evaluation, further assignment of
patients to the different dose levels would continue by randomiza-
tion.
For the feasibility evaluation of the four dose-levels, a criterion
analogous to classical phase I studies was applied and cohorts of
three patients were enrolled. If no patient out of three, or less than
three out of six patients, experienced unacceptable toxicity by the
third cycle, that level was considered feasible and the multicenter
phase II study at that dose could start. Unacceptable toxicity was
defined as any of the following toxic events occurring during any
of the first three cycles: grade 4 leukopenia or neutropenia or
febrile neutropenia (fever > 38° C with neutrophils < 1000 mm3),
grade 3–4 thrombocytopenia or vomiting or mucositis or neuro-
toxicity, and grade ≥ 2 organ toxicity (except hair loss).
The phase II studies, separately at each feasible dose-level, were
planned according to a single-arm design with p0 = 0.15, p1 = 0.30,
α = 5%, β = 20%. The planned number of patients to be recruited
was 42 for each study; 10 objective responses were required in
order to define a dose-level active enough to warrant further
studies. Recruitment of patients at the different dose-levels was
made sequentially (level 1 → level II → level III); immediately
after the end of the feasibility study, assignment of patients to the
three feasible dose-levels was done by a randomization procedure,
with a computer-driven minimization technique that accounted for
centre, stage and PS as stratifying variables.
Statistical analysis
No formal statistical comparisons among dose-levels were
performed. For response rates and unacceptable toxicity rates,
95% exact confidence intervals were reported. Time-to-progres-
sion (TTP) was defined as the interval elapsed between date of
recruitment and the date of ascertained tumour progression or of
death without evidence of disease progression. Survival was
defined as the time elapsed between the date of recruitment and
the date of death or the date of the last follow-up visit. Time-to-
progression and survival curves were estimated by the
Kaplan–Meier product limit method (Kaplan and Meier, 1958).
RESULTS
Feasibility
From February 1997 to February 1998, 15 patients entered the
study; their characteristics are reported in column 1 of Table 1.
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males (80%), with stage IV disease (93.3%), and with a relatively
good PS (ECOG 1 in 73.3%). No unacceptable toxicity was
observed in the cohorts of three patients treated at level I and at
level III. At level II, one patient out of six had grade 2 neutropenia
preventing treatment on day 8 and grade 3 peripheral neuropathy.
At level IV, the first three patients all suffered grade 4 neutropenia.
Thus, levels I, II and III were considered feasible, while level IV
was considered unfeasible.
Phase II studies
From May 1997 to November 1998, 128 patients were enrolled
from 20 participating centres. Nine centres enrolling five or more
patients accounted for 82.5% of the total number of patients
entered. Dose-level was assigned sequentially to the first 75
patients and by minimization to the remaining 53. After registra-
tion, one patient, at level III, was excluded because he refused
chemotherapy and another, at level II, was excluded because
chemotherapy had been started before registration. Thus, 43, 42
and 41 patients were evaluated at levels I, II and III respectively.
The main characteristics of the patients were similar in the three
groups (Table 1). Overall, median age was 63 years (range 46–69);
males were prevalent (88.1%); most patients were well-performing
with PS 0 in one-third and PS 1 in half of the sample; 75.4% of the
patients had stage IV disease. More than the half of the patients
had three or more sites of disease.
Compliance of patients was good. The rate of patients receiving
three or more cycles was 69.0% overall, without variations
according to dose-level (69.8%, 69.0% and 68.3% at levels I, II
and III, respectively). Considering the first three cycles, 76.2% of
patients regularly received chemotherapy on day 8; day-8 treat-
ment was withdrawn once in 19.0%, twice in 3.2% and three times
in 1.6%. Again, there was no dose-level effect on compliance to
day 8 treatment.
Treatment toxicity was mild with no death at any dose-level.
Overall, unacceptable toxicity, as defined above (with the exclu-
sion of criteria related to treatment delay that have been described
in the compliance paragraph), occurred in 19.8% (95% CI
12.8–26.8%). Higher rates of unacceptable toxicity were observed
with higher dose-levels: 16.3%, 19.0% and 24.4% at levels I, Ii
and III, respectively. Severe haematological toxicities (Table 2)
were grade 4 non-symptomatic thrombocytopenia (one case at
each level) and grade 4 anaemia (one case at level III). No febrile
neutropenia was recorded. Seven patients (5.6%) required blood
transfusions (two, one and four at the three levels, respectively).
Fatigue was the most common non-haematological toxicity (Table
3), and was severe in 8.7% of patients. Grade 4 constipation and
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Table 1 Characteristics of patients (percentages in brackets)
Variable Feasibility Phase II
level I level II level III total
(n = 15) (n = 43) (n = 42) (n = 41) (n = 126)
Centre by number of pts
≥ 5 pts 15 (100) 33 (76.7) 34 (81.0) 37 (90.2) 104 (82.5)
< 5 pts – 10 (23.3) 8 (19.0) 4 (9.8) 22 (17.5)
Sex
males 12 (80.0) 38 (88.4) 38 (90.5) 35 (85.4) 111 (88.1)
females 3 (20.0) 5 (11.6) 4 (9.5) 6 (14.6) 15 (11.9)
Age
median 59 62 63 63 63
range 38–68 46–69 46–69 49–69 46–69
ECOG PS
0 2 (13.3) 15 (34.9) 13 (31.0) 14 (34.2) 42 (33.3)
1 11 (73.3) 20 (46.5) 21 (50.0) 21 (51.2) 62 (49.2)
2 2 (13.3) 8 (18.6) 8 (19.0) 6 (14.6) 22 (17.5)
Stage
IIIb 1 (6.7) 10 (23.3) 10 (23.8) 11 (26.8) 31 (24.6)
IV 14 (93.3) 33 (76.7) 32 (76.2) 30 (73.2) 95 (75.4)
Histology
squamous 7 (46.7) 14 (32.6) 16 (38.1) 20 (48.8) 50 (39.7)
adenocarcinoma 8 (53.3) 21 (48.8) 17 (40.5) 17 (41.5) 55 (43.7)
large cells – 1 (2.3) 2 (4.8) – 3 (2.4)
not defined – 7 (16.3) 7 (16.7) 3 (7.3) 17 (13.5)
mixed – – – 1 (2.4) 1 (0.8)
Weight loss (three missing)
none 12 (80.0) 27 (65.9) 23 (54.8) 19 (47.5) 69 (56.1)
≤ 10% – 11 (26.8) 17 (40.5) 18 (45) 46 (37.4)
>10% 3 (20.0) 3 (7.3) 2 (4.8) 3 (7.5) 8 (6.5)
No. of tumour sites
0 1 (6.7) – – – –
1 2 (13.3) 3 (7.0) 5 (11.9) 4 (9.8) 12 (9.5)
2 6 (40.0) 17 (39.5) 14 (33.3) 12 (29.3) 43 (34.1)
3 6 (40.0) 11 (25.6) 14 (33.3) 16 (39.0) 41 (32.5)
4 – 10 (23.3) 7 (16.7) 6 (14.6) 23 (18.3)
5 – 1 (2.3) 1 (2.4) 3 (7.3) 5 (4.0)
6 – – 1 (2.4) – 1 (0.8)
7 – 1 (2.3) – – 1 (0.8)grade 4 mucositis were recorded in one case each, both at level III.
Liver toxicity, measured by increase of AST and ALT, was
reported at level I in two cases (one grade 2 and one grade 4), at
level II in two other cases (one grade 2 and one grade 3) and at level
III in one case only (grade 3). Heart rhythm disturbances, possibly
related to treatment, were reported in one patient, at level III.
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Table 2 Haematological toxicity (percentages in brackets)
Toxicity level I level II level III total
(n = 43) (n = 42) (n = 41) (n = 126)
Leukopenia
grade 3 1 (2.3) 7 (16.7) 7 (17.1) 15 (11.9)
grade 4 2 (4.7) 2 (4.8) 4 (9.8) 8 (6.3)
Neutropenia
grade 3 4 (9.3) 10 (23.8) 5 (12.2) 19 (15.1)
grade 4 2 (4.7) 6 (14.3) 7 (17.1) 15 (11.9)
Infections
grade 2 – – 1 (2.4) 1 (0.8)
grade 3 – 3 (7.1) 1 (2.4) 4 (3.2)
Thrombocytopenia
grade 3 – 2 (4.8) – 2 (1.6)
grade 4 1 (2.3) 1 (2.4) 1 (2.4) 3 (2.4)
Bleeding
grade 1 – 1 (2.4) – 1 (0.8)
Anaemia
grade 3 – 1 (2.4) 2 (4.9) 3 (2.4)
grade 4 – – 1 (2.4) 1 (0.8)
Fever
grade 2 6 (14.0) 6 (14.3) – 12 (9.5)
grade 3 – 1 (2.4) 1 (2.4) 2 (1.6)
Table 3 Non-haematological toxicity (percentage in brackets)
Toxicity level I level II level III total
(n = 43) (n = 42) (n = 41) (n = 126)
Fatigue
grade 3 2 (4.7) 1,5 (11.9) 4 (9.8) 11 (8.7)
Vomiting
grade 3 – 1 (2.4) 1 (2.4) 2 (1.6)
Diarrhoea
grade 2 – 2 (4.8) – 2 (1.6)
grade 3 1 (2.3) – – 1 (0.8)
Mucositis
grade 2 2 (4.7) – 1 (2.4) 3 (2.4)
grade 4 – – 1 (2.4) 1 (0.8)
Constipation
grade 2 4 (9.3) 2 (4.8) – 6 (4.8)
grade 4 – – 1 (2.4) 1 (0.8)
Neuropathy
grade 3 1 (2.3) 1 (2.4) – 2 (1.6)
CNS
grade 1 3 (7.0) – 1 (2.4) 4 (3.2)
Cutaneous
grade 2 1 (2.3) 1 (2.4) 1 (2.4) 3 (2.4)
Heart rhythm
grade 2 – – 1 (2.4) 1 (0.8)
Pulmonary
grade 2 1 (2.3) 1 (2.4) – 2 (1.6)
grade 3 – 1 (2.4) – 1 (0.8)
Liver
grade 2 1 (2.3) 1 (2.4) – 2 (1.6)
grade 3 – 1 (2.4) 1 (2.4) 2 (1.6)
grade 4 1 (2.3) – – 1 (0.8)
Bone pain
grade 2 1 (2.3) 2 (4.8) 1 (2.4) 4 (3.2)
grade 4 1 (2.3) – – 1 (0.8)
Hair loss
grade 2 1 (2.3) 2 (4.8) 4 (9.8) 7 (5.6)Phlebitis was reported in three (2.4%) patients, hair loss was infre-
quent, reaching grade 2 in seven (5.6%) patients. No renal toxicity
was recorded.
Overall, 33 patients (26.2%, 95% CI 18.5–33.9) had an objec-
tive response: complete in one case and partial in 32 (Table 4).
According to study rules, the minimum expected number of
responses was surpassed at levels I (12 partial responses, 27.9%,
95% CI 15.3%–43.7%) and III (one complete response and 11
partial responses, 29.3%, 95%, CI 16.1–45.5), but not at level II
(nine partial responses, 21.4%, 95% CI 10.3–36.8). The disease
stabilized in 29 (23.0%) patients.
Survival
As of November 30 1999, 85 patients had had a clinical or radio-
logical evident tumour progression and 107 had died (33 of these,
without evidence of disease progression, were considered as
progressed on the date of death). Median TTP was 18 weeks (95%
CI 14–22); 6-month and 1-year TTP were 33% and 16%, respec-
tively; out of eight patients not progressed, four had a follow-up
time longer than 1 year. Median survival was 33 weeks (95% CI
28–40); 6-month, 12-month and 18-month survival being 60%,
33% and 17%, respectively. As shown in Figure 1, overall survival
curves of the total study population and those of subgroups treated
at different dose-levels are very similar.
Quality of life
Compliance to QoL questionnaires progressively decreased across
the cycles (89.7% at baseline and 69.8%, 59.5%, 35.7%, 28.6%,
26.2% before the second, third, fourth, fifth and sixth cycle,
respectively). Figure 2 shows the mean scores of the global health
status item for all patients (white symbols) and for subgroups of
patients according to the time of the last QoL assessment,
combining patients who completed four or more questionnaires.
Patients with a lower (worse) baseline global health status score
tended to drop out of the study earlier than patients with a higher
(better) score. Furthermore, a slight worsening of the score was
observed within each subgroup although an improvement was
apparent when measuring mean values in the whole group,
because of the selection bias due to early drop-out of patients with
unfavourable prognosis.
DISCUSSION
The principal strategic consideration underlying this study was
that cisplatin-based chemotherapy only produces a modest
survival advantage in advanced NSCLC (NSCLC Collaborative
Gemcitabine plus vinorelbine in advanced NSCLC 711
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Table 4 Treatment activity (percentages in brackets)
Response level I level II level III total
(n = 43) (n = 42) (n = 41) (n = 126)
Complete – – 1 (2.4) 1 (0.8)
Partial 12 (27.9) 9 (21.4) 11 (26.8) 32 (25.4)
Response rate 27.9% 21.4% 29.3% 26.2%
95% exact CI 15.3–43.7 10.3–36.8 16.1–45.5 18.5–33.9
Stable disease 11 (25.6) 11 (26.2) 7 (17.1) 29 (23.0)
Progression 15 (34.9) 19 (45.2) 14 (34.1) 48 (38.1)
Not evaluated 5 (11.6) 3 (7.1) 8 (19.5) 16 (12.7)
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Figure 1 Overall survival curves
Figure 2 Global health status mean scores by QoL drop-out timingGroup, 1995), and is frequently associated with toxicity. Thus, we
aimed to look for a less toxic but sufficiently active treatment to be
subsequently compared in a randomized trial to cisplatin-based
chemotherapy.
Knowledge of the efficacy of chemotherapy without cisplatin
for advanced NSCLC has for a long time been based on the results
of clinical trials performed many years ago. Meta-analysis of trials
comparing chemotherapy without cisplatin vs best supportive care
yielded negative results. But the trials included in the meta-
analysis explored the use of long-term alkylating agents or etopo-
side as a single agent (NSCLC Collaborative Group, 1995), which
are no longer used because of their very low activity.
Clinical trials comparing regimens containing mitomycin C and
vindesine (MV) vs cisplatin-based treatment partially modified
our perspective. In fact, two randomized trials of MV vs cisplatin-
containing treatment yielded contrasting results (Shinkai et al,
1985; Luedke et al, 1990). In another randomized trial comparing
MV vs mitomycin C plus ifosfamide vs cisplatin plus etoposide,
no significant differences were seen in response rate and survival
among the three arms but, on the basis of toxicity, mitomycin C
plus vindesine was felt to be the preferred regimen (Gatzmeier et
al, 1991). Furthermore, in a phase III trial on 204 metastatic
NSCLC patients in which mitomycin C plus etoposide plus vinde-
sine (MEV) was compared with cisplatin plus mitomycin C plus
vindesine (MVP), we observed no differences in relief of symp-
toms, response rate or survival among the two arms, but MEV had
a significantly lower toxicity (Gridelli et al, 1996).
The advent of new active and well-tolerated drugs prompted
further research in this field, also in the light of the increasing
importance of QoL as a major end-point of the treatment of
advanced NSCLC.
Gem Vin combination was feasible at three out of four tested
dose-levels. At the dose of 1200 mg m–2 and 30 mg m–2, it was less
manageable because of severe neutropenia. As we had no indica-
tion that higher doses could improve patient outcome, and because
low toxicity was among the main objectives in view of a QoL-
based comparison with cisplatin-containing chemotherapy, we
explored the activity and toxicity of Gem Vin at all feasible levels.
The final choice of the optimal schedule to be compared with
cisplatin-containing chemotherapy was qualitatively based on the
balance between activity and toxicity. In this view, the first dose-
level (gemcitabine 1000 mg m–2 + vinorelbine 25 mg m–2, days 1
and 8, every 3 weeks) seems to be the optimal choice, being simi-
larly active and less toxic than the other two dose-levels studied.
It has recently been suggested (Chen et al, 1999) that the
sequence of administration of the two drugs might affect activity
and toxicity of the Gem Vin combination. Chen et al found that
giving vinorelbine first produced a higher response rate, as
compared to a previous study where gemcitabine was given first.
Also, a higher degree of toxicity, mainly myelosuppression, was
observed with vinorelbine given first. In our study it was planned
to give gemcitabine as first drug. However, 15 patients received
the inverse sequence of drugs. Although this kind of analysis was
not planned, we checked whether there was any effect on the
outcomes of the sequence of drug administration. We found no
association between the sequence and response rate (31/111, 28%
with Gem→ Vin; 2/15, 13% with Vin→ Gem; P = 0.23). Instead,
the Vin→ Gem was more toxic as for leukopenia (chi-square for
trend P = 0.03) and neutropenia (chi-square for trend P = 0.0074);
namely, 9% of patients had grade 4 neutropenia with Gem→ Vin vs
33% with Vin→ Gem. There was no other significant difference in
toxicity between the two schedules. Thus, our data are contrasting
with those of Chen for activity and consistent for toxicity.
However, both our analysis and the data of Chen may only be
considered as suggestive, due to a number of biases that could
affect retrospective analysis and comparisons with historical
controls.
An interesting finding emerged from QoL analysis, which we
had already previously noted in elderly patients with advanced
NSCLC (ELVIS group, 1999). Global health status mean scores,
which are reliable indicators of QoL, were closely related to the
timing of patients’ drop-out. Therefore, calculations made on the
whole patient population are clearly misleading and over-opti-
mistic, because a relevant rate of progressions or deaths occur
quite early in patients with advanced NSCLC given the natural
history of the disease. Consequently, QoL unadjusted for the drop-
out process, as is frequently reported in studies on NSCLC, may
be misleading and could lead to incorrect conclusions.
To our knowledge, this is the largest and most comprehensive
phase II evaluation of a new non-cisplatin-based treatment
regimen in advanced NSCLC. As for the combination gemcitabine
plus vinorelbine, two phase II trials have recently been reported,
with relevant differences as for schedule of treatment or patient
selection as compared to the present one. Isokangas et al (1999)
explored two different schedules in a group of adult patients with
advanced NSCLC, including a subgroup with stage IIIb disease
without metastatic supraclavicular nodes or pleural effusion, and
including a subgroup of elderly patients (median age 59, age range
40–78). They found that a 28-day cycle with vinorelbine 30 mg
m–2 on days 1, 8, 15 and 22 and gemcitabine 1000 mg m–2 on days
1, 8 and 15 was too toxic, mainly because of severe neutropenia
producing frequent delays of drug administration; in addition,
three out of 12 patients treated with this schedule died because of
toxicity. Further, 32 patients were treated with a fortnightly
schedule with vinorelbine 35 mg m–2 and gemcitabine 1200 mg
m–2 both given on days 1 and 15 of each 28-day cycle. The overall
response rate (including those patients considered not evaluable by
the Authors because they had received less than two cycles) was
40.6% (95% CI 23.7–59.4%, 13/32 patients), possibly favoured
some patients with less advanced stage IIIb disease. As for toxi-
city, the Authors signal that 24% of patients suffered grade 3–4
neutropenia with the fortnightly schedule. Overall, the fortnightly
administration, which implies a prolongation of overall treatment
duration as compared to the Gem Vin schedule we applied, does
not seem to produce better results. Feliu et al (1999) selected 49
patients with advanced NSCLC for treatment with a combination
of gemcitabine plus vinorelbine because they were > 70 years old
(38/49 patients, 78%) or, if younger, they had some contraindica-
tions to receiving cisplatin. They also included 19 patients (39%)
with stage IIIb disease eligible for radiotherapy. Vinorelbine 25
mg m–2 and gemcitabine 1000 mg m–2 were given on days 1, 8 and
15 every 28 days. Toxicity was mild; the overall response rate was
26.5% (95% CI 14.9–41.1%), and median survival was 33 weeks.
As for other combinations including new drugs, a phase II trial on
46 patients treated with docetaxel plus vinorelbine plus G-CSF
support showed relevant toxicity (four toxic deaths, 24% of
patients with neutropenic fever, 43% of patients requiring hospi-
talization) and a 33% response rate (Kourousis et al, 1998).
Another phase II trial of docetaxel plus gemcitabine plus G-CSF
(Georgulias et al, 1999) in 51 patients showed a 37% response rate
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opinion, to stress that both the latter two treatment schedules
required the administration of supportive G-CSF by principle, with
relevant impact on cost of treatment and, possibly, on quality of
life.
The study design applied in the present phase II study might
look unusual. It was prompted by the consideration that no formal
phase I study had been published at the time the protocol was
drawn, but the treatment had been sporadically tested in clinical
practice for patients not eligible to cisplatin-based chemotherapy,
at different doses, by many of the participating investigators. Thus,
a short feasibility study, based on a common phase I design, was
planned at each dose-level. In addition, investigators agreed
initially that all the four dose-levels on study could probably be
active against the disease, although with possibly different toxicity
rates. Thus, we decided that a phase II trial was worth conducting
at all feasible doses. The procedure of minimization, used to
randomize 42% of patients on-study, did produce similar distribu-
tion of main baseline (possibly prognostic) characteristics of
patients among the three dose-levels. Although inter-arm compar-
isons among dose-levels were not formally applied, the attained
sample and the observed results rule out the possibility that large
differences of activity may exist among tested doses (Simon et al,
1985). Further, overall results represent a very reliable estimate of
treatment activity, due to the large sample size in this phase II
study. This is reassuring, in the light that for the proposed phase III
study (comparing GemVin vs cisplatin-based chemotherapy) some
concern could arise as for the risk of under-treatment with
GemVin.
According to the results of the present study, a two-arm phase
III study comparing a combination of gemcitabine (1000 mg m–2)
and vinorelbine (25 mg m–2) vs the cisplatin-based chemotherapy
currently used in Italy (cisplatin plus gemcitabine or cisplatin plus
vinorelbine) is ongoing. The primary end-point of this trial is QoL
and an interim survival analysis is planned to protect patients from
large survival differences between the two arms.
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